Table 2

Outcomes at 6 and 12 months for intervention and active-control patients

Baseline 6-month change12-month changeDifference in change*P value**
Mean (SD)Mean (SD)Mean (SD)
PHQ
 Intervention14.5 (3.8)−6.6 (5.0)−7.3 (5.6)2.00.015
 Active control14.6 (3.5)−4.6 (5.8)−5.2 (5.7)
A1C (%)
 Intervention7.5 (1.8)−0.2 (1.1)−0.2 (1.3)−0.10.47
 Active control7.8 (1.7)−0.4 (0.9)−0.2 (1.1)
A1C (mmol/mol)
 Intervention58 (19.7)−2.2 (12.0)−2.2 (14.2)−1.30.47
 Active control62 (18.6)−4.4 (9.8)−2.2 (12.0)
SBP (mmHg)
 Intervention126 (15.5)−2.3 (13.8)−4.8 (13.8)2.50.75
 Active control124 (16.5)−3.1 (21.1)−2.5 (17.8)
LDL-cholesterol (mmol/L)
 Intervention2.2 (0.9)−0.2 (0.6)−0.2 (0.7)0.080.39
 Active control2.1 (0.8)−0.2 (0.6)−0.1 (0.9)
PCS-12
 Intervention36.0 (10.0)1.5 (6.3)2.8 (6.9)−0.70.54
 Active control34.9 (9.8)2.6 (7.3)3.1 (9.0)
MCS-12
 Intervention34.1 (7.7)6.1 (8.1)7.6 (9.5)2.30.09
 Active control36.6 (7.3)4.7 (9.7)4.4 (8.4)
EQ-5D
 Intervention0.71 (0.16)0.01 (0.11)0.03 (0.10)−0.020.23
 Active control0.67 (0.17)0.04 (0.10)0.04 (0.12)
PAID-5
 Intervention1.6 (1.0)−0.4 (0.8)−0.6 (0.8)0.30.03
 Active control1.3 (1.0)−0.1 (0.9)−0.2 (0.9)
PACIC-11
 Intervention34.7 (27.9)18.1 (30.0)5.50.25
 Active control34.4 (25.0)12.6 (26.2)
  • *Difference in change between intervention and active control over 12 months adjusted for time.

  • **P value from a random-effects model comparing changes in intervention and active-control patients at 6 and 12 months.